From the potent and selective μ opioid receptor agonist H-Dmt-D-Arg-Phe-Lys-NH2 to the potent δ antagonist H-Dmt-Tic-Phe-LyS(Z)-OH

Journal of Medicinal Chemistry

Volumn 48, Issue 17, 2005, Pages 5608-5611

  Balboni, Gianfranco ^a,b   Cocco, Maria Teresa ^a   Salvador, Severe ^b   Romagnoli, Romeo ^b   Sasaki, Yusuke ^c   Okada, Yoshio ^d   Bryant, Sharon D ^e   Jinsmaa, Yunden ^e   Lazarus, Lawrence H ^e  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

^d KOBE GAKUIN UNIVERSITY   (Japan)

^e NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(2',6' DIMETHYLTYROSINE)TYROSYL DEXTRO ARGINYLPHENYLALANYLLYSINAMIDE; 2',6' DIMETHYLTYROSINE 1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBOXYLIC ACID PHENYLALANYLLYSINE; ANALGESIC AGENT; CARBOXYLIC ACID; DELTA OPIATE RECEPTOR ANTAGONIST; MU OPIATE RECEPTOR AGONIST; TYROSYL DEXTRO ARGINYLPHENYLALANYLLYSINAMIDE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; CARBOXY TERMINAL SEQUENCE; DRUG POTENCY; DRUG SELECTIVITY; HYDROLYSIS; RECEPTOR AFFINITY; RECEPTOR BINDING; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ANIMALS; BINDING, COMPETITIVE; GUINEA PIGS; ILEUM; MALE; MICE; MUSCLE CONTRACTION; MUSCLE, SMOOTH; OLIGOPEPTIDES; RATS; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, MU; SYNAPTOSOMES; VAS DEFERENS;

EID: 23944458062     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0504959     Document Type: Article

References (22)

1. 2, negative log of the molar concentration required to double the agonist concentration to achieve the original response; Pe, petroleum ether; TFA, trifluoroacetic acid; Tic, 1,2,3,4-tetrahydroisoquinoline-3- carboxylic acid; TLC, thin-layer chromatography; WSC, 1-ethyl-3-(′- dimethylaminopropyl)carbodiimide-HCl; Z, benzyloxycarbonyl.
2. Fang, F. G.; Fields, H. L.; Lee, N. M. Action at the μ receptor is sufficient to explain the supraspinal analgesic effects of opiates. J. Pharmacol. Exp. Ther. 1986, 238, 1039-1044.
3. Matthes, H. W.; Maldonado, R.; Simonin, F.; Valverde, O.; Slowe, S.; Kitchen, I.; Befort, K; Dierich, A.; Le Meur, M.; Dolle, P.; Tzavara, E.; Hanoune, J.; Roques, B. P.; Kieffer, B. L. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the μ-opioid-receptor gene. Nature 1996, 383, 819-823.
4. 5]enkephalin-induced analgesia. Eur. J. Pharmacol. 1997, 324, R1-R2.
5. Abdelhamid, E. E.; Sultana, M.; Portoghese, P. S.; Takemori, A. E. Selective blockage of μ opioid receptors prevents the development of morphine tolerance and dependence in mice. J. Pharmacol. Exp. Ther. 1991, 258, 299-303.
6. Nitsche, F.; Schuller, A. G.; King, M. A.; Zengh, M.; Pasternak, G. W.; Pintar, J. E. Genetic dissociation of opiate tolerance and physical dependence in δ-opioid receptor-1 and preproenkephalin knock-out mice. J. Neurosci. 2002, 22, 10906-10916.
7. Gaveriaux-Ruff, C.; Filliol, D.; Simonin, F.; Matthes, H. W.; Kieffer, B. L. Immunosuppression by δ-opioid antagonist NTI: δ- and triple μ/δ/κ opioid receptor knockout mice reveal a nonopioid activity. J. Pharmacol. Exp. Ther. 2001, 298, 1193-1198.
8. Chen, Y. L.; Law, P. Y.; Loh, H. H. Inhibition of akt/protein kinase B signalling by naltrindole in small cell lung cancer cells. Cancer Res. 2004, 64, 8723-8730.
9. Balboni, G.; Salvadori, S.; Guerrini, R.; Negri, L.; Giannini, E.; Bryant, S. D.; Jinsmaa, Y.; Lazarus, L. H. Synthesis and opioid activity of N,N-dimethyl-Dmt-Tic-NH-CH(R)-R′ analogues: acquisition of potent δ antagonism. Bioorg. Med. Chem. 2003, 11, 5435-5441.
10. Salvadori, S.; Balboni, G.; Gerrini, R.; Tomatis, R.; Bianchi, C.; Bryant, S. D.; Cooper, P. S.; Lazarus, L. H. Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary δ opioid antagonist activity. J. Med. Chem. 1997, 40, 3100-3108.
11. Schiller, P. W.; Nguyen, T. M.-D.; Berezowska, L; Dupuis, S.; Weltrowska, G.; Chung, Nga N.; Lemieux, C. Synthesis and in vitro opioid activity profiles of DALDA analogues. Eur. J. Med. Chem. 2000, 35, 895-901.
12. Balboni, G.; Salvadori, S.; Guerrini, R.; Negri, L.; Giannini, E.; Bryant, S. D.; Jinsmaa, Y.; Lazarus, L. H. Direct influence of C-terminally substituted amino acids in the Dmt-Tic pharmacophore on δ-opioid receptor selectivity and antagonism. J. Med. Chem. 2004, 47, 4066-4071 and references cited herein.
13. Tancredi, T.; Salvadori, S.; Amodeo, P.; Picone, D.; Lazarus, L. H.; Bryant, S. D.; Guerrini, R.; Marzola, G.; Temussi, P. A. Conversion of enkephalin and dermorphin into δ-selective opioid antagonists by single-residue substitution. Eur. J. Biochem. 1994, 224, 241-247.
14. Bryant, S. D.; Jinsmaa, Y.; Salvadori, S.; Okada, Y.; Lazarus, L. H. Dmt and opioid peptides: a potent alliance. Biopolymers 2003, 71, 86-102.
15. Schiller, P. W.; Weltrowska, G.; Nguyen, T. M.-D.; Wilkes, B. C.; Chung, N. N.; Lemieux, C. Conformationally restricted deltorphin analogues. J. Med. Chem. 1992, 35, 3956-3961.
16. Portoghese, P. S.; Sultana, M.; Nagase, H.; Takemori, A. E. Application of the message-address concept in the design of highly potent and selective non-peptide δ opioid receptor antagonists. J. Med. Chem. 1988, 31, 281-282.
17. Schiller, P. W.; Weltrowska, G.; Nguyen, T. M.-D.; Wilkes, B. C.; Chung, N. N.; Lemieux, C. TIPP[Ψ]: a highly potent and stable pseudopeptide δ opioid receptor antagonist with extra-ordinary δ selectivity. J. Med. Chem. 1992, 36, 3182-3187.
18. Balboni, G.; Salvadori, S.; Guerrini, R.; Negri, L.; Giannini, E.; Jinsmaa, Y.; Bryant, S. D.; Lazarus, L. H. Potent δ-opioid receptor agonists containing the Dmt-Tic pharmacophore. J. Med. Chem. 2002, 45, 5556-5563.
19. Zadina, J. E.; Hackler, L.; Ge, L.-I.; Kastin, A. J. A potent and selective endogenous agonist for the μ-opiate receptor. Nature 1997, 386, 499-502.
20. Schiller, P. W.; Nguyen, T. M.-D.; Weltrowska, G.; Wilkes, B. C.; Marsden, B. J.; Lemieux, C.; Chung, N. N. Differential stereochemical requirements of μ vs δ opioid receptors for ligand binding and signal transduction: development of a class of potent and highly δ-selective peptide antagonists. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 11871-11875.
21. Schiller, P. W.; Weltrowska, G.; Berezowska, I.; Nguyen, T. M.-D.; Wilkes, B. C.; Lemieux, C.; Chung, N. N. The TIPP opioid peptide family: development of δ antagonists, δ agonists, and mixed μ agonist/δ antagonists. Biopolymers 1999, 51, 411-425.
22. 1 dermorphin analogues. Farmaco, Ed. Sci. 1987, 42, 931-940.